MAPS Public Benefit Corporation announced this week that it has submitted a new drug application seeking the approval of MDMA-assisted…
MAPS is now on track to proposing MDMA as a treatment for PTSD from the FDA in 2024.
Trial found “no serious adverse events were observed in either the MDMA group or the control group.”